
These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.

These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.

Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.

Brett King, MD, PhD, discusses how the deuruxolitinib approval impacts the treatment landscape of alopecia areata.

A new study found claims for services of opioid treatment programs rose among Medicare beneficiaries after Medicare started covering them.

Findings suggest the current emphasis on targeting inflammation to mitigate fibrosis in MASLD may be incorrect, citing the minimal impact of LBP function loss on fibrosis.

Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.

A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.

Using NHANES data, researchers calculated AGILE 3 + and AGILE 4 scores to determine the prevalence of advanced fibrosis and cirrhosis in patients with MASLD in the US.

In this part of our 5-part series, Gus Alva, MD discusses the next steps in research for long-term effects and broader applications of MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD explores MDMA’s neurochemical impact and the need for ongoing research.

In this part of our 5-part series, Gus Alva, MD highlights the importance of education and overcoming skepticism about MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.

In this part of our 5-part series, Gus Alva, MD discusses the unmet need in PTSD treatment and the potential of MDMA-assisted therapy.

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.

Primary and secondary pharmacokinetic parameters through day 75 were similar across treatment arms.

These new data were announced by Aquestive Therapeutics and if approved, Anaphylm Sublingual Film could be the first orally-delivered, non-invasive severe allergy treatment.

These data highlighted new findings on the experiences of children aged 6 to 11 with uncontrolled type 2 asthma treated with dupilumab.

A study demonstrated a smartphone app provides comparable benefits to cognitive behavior or mindfulness-based therapy, widening the supply gap for mental health care.

New research suggests combined treatment with fecal microbiota transplant and anti-PD-1 inhibitors may help overcome immune checkpoint inhibitor resistance in gastrointestinal cancers.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

These new phase 3 findings from ARCADIA 1 and 2 highlight the effects of nemolizumab in combination with either topical corticosteroids or topical calcineurin inhibitors.

Personalized text messages can boost physical activity in cardiac rehab patients, especially in early stages, but effectiveness varies by time and device, study finds.

Positive topline results from the phase 2 SPRING trial highlight CM-101’s anti-fibrotic, anti-inflammatory, and anti-cholestatic effects in primary sclerosing cholangitis.

Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.

The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.

The expanded label includes use in patients with PFIC 12 months of age and older as well as a higher concentration formulation.

This meta-analysis was conducted to compare the efficacy and safety of lebrikizumab to other systemic treatments for patients with atopic dermatitis.

In an interview Adrian Quartel, MD, discusses the next steps for evaluating KP1077 in idiopathic hypersomnia after the phase 2 study.

The nomogram was constructed using independent risk factors for early cirrhosis and demonstrated greater diagnostic accuracy than current noninvasive fibrosis tests.

These data highlighted the association of moderate air pollution exposure during pregnancy, infancy, and early childhood on pulmonary function at school age.